

Haematologica  
HAEMATOL/2019/234179  
Version 2

Prolonged treatment free remission in chronic myeloid leukemia  
patients with previous BCR-ABL1 kinase domain mutations

Simone Claudiani, Jane F Apperley, Afzal Khan, Jamshid S Khorashad,  
and Dragana Milojkovic

Disclosures: Acknowledgements J.F.A. and D.M. acknowledge the support of the Imperial College NIHR Biomedical Research Centre. The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Conflict-of-Interest Disclosure S.C. Honoraria from Incyte and Pfizer; J.F.A. Honoraria from Pfizer, BMS, Incyte and Novartis; A.K. research funding from Novartis; J.K. Honoraria from Novartis; D.M. Honoraria from Pfizer, BMS, Incyte and Novartis.

Contributions: Authorship SC designed the study, collected and analysed the data and wrote the manuscript; J.F.A., A.K. and J.K. reviewed the manuscript; D.M. designed the study, collected the data and wrote the manuscript.